DaVita (NYSE:DVA) Price Target Raised to $250.00

DaVita (NYSE:DVA) had its target price upped by Truist Financial from $205.00 to $250.00 in a report issued on Tuesday morning, MarketBeat Ratings reports. Truist Financial currently has a hold rating on the stock.

Other analysts have also issued research reports about the company. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their price target for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. UBS Group lifted their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Barclays increased their price target on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Finally, TD Cowen upped their price objective on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $216.50.

DaVita Price Performance

DVA stock opened at $233.75 on Tuesday. The stock has a market capitalization of $15.01 billion, a P/E ratio of 21.68, a P/E/G ratio of 0.76 and a beta of 0.88. The business has a 50-day moving average of $209.17 and a 200-day moving average of $163.98. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $239.64.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the business earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts expect that DaVita will post 15.07 EPS for the current year.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On DaVita

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB raised its holdings in shares of DaVita by 3.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 10,700 shares of the company’s stock worth $2,381,000 after buying an additional 400 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in shares of DaVita in the 2nd quarter valued at $229,000. Polianta Ltd acquired a new position in DaVita in the 2nd quarter worth about $2,069,000. Assenagon Asset Management S.A. increased its stake in shares of DaVita by 30.5% in the second quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after buying an additional 10,477 shares during the period. Finally, Chapin Davis Inc. bought a new position in DaVita in the 2nd quarter valued at approximately $1,012,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.